Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has received a consensus rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $35.75.

A number of brokerages recently weighed in on XNCR. JPMorgan Chase & Co. lifted their target price on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Royal Bank of Canada lifted their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Wedbush reissued an “outperform” rating and set a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $34.00 price target (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th.

Insider Activity at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 3,366 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total transaction of $80,851.32. Following the completion of the sale, the chief executive officer now owns 352,615 shares in the company, valued at $8,469,812.30. This trade represents a 0.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the sale, the vice president now owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

Hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. boosted its stake in Xencor by 147.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after acquiring an additional 1,858,440 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of Xencor in the 1st quarter valued at about $24,557,000. Logos Global Management LP lifted its position in shares of Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after purchasing an additional 850,000 shares during the last quarter. RA Capital Management L.P. acquired a new position in Xencor in the third quarter worth about $11,563,000. Finally, RTW Investments LP acquired a new position in Xencor in the third quarter worth about $11,563,000.

Xencor Price Performance

XNCR opened at $23.63 on Wednesday. Xencor has a 1 year low of $15.31 and a 1 year high of $26.84. The company’s 50 day simple moving average is $21.19 and its 200 day simple moving average is $20.37. The stock has a market capitalization of $1.65 billion, a PE ratio of -7.38 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same quarter last year, the firm posted ($0.40) earnings per share. Xencor’s revenue was down 81.9% on a year-over-year basis. As a group, sell-side analysts expect that Xencor will post -3.79 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.